Based on an observed progressive course of chronic pain, patients may require alternative treatments. Systemic analgesics are used initially to help control pain.1,2 With time, patients may become refractory to or intolerant of systemic analgesics, which may limit their ability to continue with this treatment.2,7
In some patients, targeted delivery of IT opioids may initially decrease the overall dose of analgesics required for pain relief, but the phenomenon of tolerance may occur.5,7,8
Important Safety Information
PRIALT is contraindicated in patients with:
- A known hypersensitivity to ziconotide or any of its formulation components.
- Any other concomitant treatment or medical condition that would render IT administration hazardous, such as the presence of infection at the microinfusion injection site, uncontrolled bleeding diathesis, and spinal canal obstruction that impairs circulation of cerebrospinal fluid (CSF).
- A pre-existing history of psychosis.
References: 1. Feinberg, American Chronic Pain Association (ACPA), 2013. 2. Munir M, Enany N, Zhang JM. Nonopioid analgesics. Anesthesiol Clin. 2007;25(4):761-774. 5. Gerber HR. Intrathecal morphine for chronic benign pain. Best Pract Res Clin Anaesthesiol. 2003;17(3):429-442. 6. PRIALT [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; February 2013. 7. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008;24(6):469-478. 8. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):436-464.